TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 373871
Drug: clindamycin (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: clindamycin (2.4 g/d) plus gentamicin (5.1 mg/kg daily)
Study: 30972991
Drug: Partial submergence
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial submergence treatment for 20 days
Study: 21721594
Drug: Diazepam autoinjector
Normalized name: Diazepam Autoinjector
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam autoinjector (10 mg)
Study: 21721594
Drug: Diazepam rectal
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam rectal gel (10 mg)
Study: 19453040
Drug: Continuous 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous 5-FU infusion (333 mg/m2/day for 7 days starting from the day of surgery) + oral HCFU (300 mg/day for 2 years starting 2 weeks after surgery) in Group B
Study: 19453040
Drug: Oral HCFU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HCFU (300 mg/day for 2 years starting 2 weeks after surgery) in Group A
Study: 15063918
Drug: Court-ordered disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Court-ordered disulfiram treatment
Study: 15063918
Drug: Voluntary disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voluntary disulfiram treatment
Study: 9018023
Drug: Gum containing
Normalized name: CONTAINER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum containing 200 mg theanine
Study: 7688204
Drug: 0.1% 13-cis-retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% 13-cis-retinoic acid cream
Study: 7688204
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base only (Control)
Study: 27746523
Drug: Granisetron 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 0.05 mg/kg
Study: 27746523
Drug: Palonosetron 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 1.5 mcg/kg
Study: 24654464
Drug: Diphereline (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphereline (GnRH agonist)
Study: 24654464
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no GnRH agonist)
Study: 18671458
Drug: Apricitabine 1200
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apricitabine 1200 mg administered after fasting
Study: 18671458
Drug: Apricitabine 1200
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apricitabine 1200 mg administered after a high-fat meal
Study: 18671458
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of fasting vs high-fat meal administration
Study: 10658408
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 100 mg before surgical incision (group-K1)
Study: 10658408
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine after laparotomy (group-K2)
Study: 10848653
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.d.
Study: 9690720
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg b.d.
Study: 7495944
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.d., intravenous drip infusion
Study: 7495944
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.d., bolus injection
Study: 26658126
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of 0.5 mg kg(‐1) twice daily
Study: 26658126
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 40 mg daily
Study: 20213013
Drug: Mucoadhesive lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucoadhesive lipid-based bioerodable tablet
Study: 18413214
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamins B(1) and B(6) tablets
Study: 15814161
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg, twice daily, for 16 weeks)
Study: 12219852
Drug: Resistance treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance treatment to deceptive persuasive messages
Study: 12219852
Drug: Resistance treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance treatment
Study: 8966498
Drug: Intermittent cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclic therapy (ICT) with etidronate
Study: 6670855
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir in an aqueous cream base
Study: 30859993
Drug: Transcranial Magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Magnetic Stimulation (TMS) treatment
Study: 30859993
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (not performed)
Study: 28344176
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) with a margin dose >20 Gy
Study: 28344176
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) with a margin dose ≤20 Gy
Study: 27123421
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose 1 μg/kg over 15 minutes, maintenance 0.5 μg/kg/h)
Study: 27123421
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (loading dose 50 mg/kg over 15 minutes, maintenance 15 mg/kg/h)
Study: 24268564
Drug: Rothschild Scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rothschild Scale for Antidepressant Tachyphylaxis® (RSAT)
Study: 24854458
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release niacin combined with laropiprant (ERN-L)
Study: 12452452
Drug: Doxorubicin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin at 80 mg/m2 x 3, followed by paclitaxel at 140 mg/m2 over 96 h x 3, then 5‐FU at doses of 1285, 1470, or 1655 mg/m2 by continuous intravenous infusion over 72 h x 3
Study: 19767092
Drug: Dose-dense regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense regimen
Study: 1953964
Drug: Tetrahydroaminoacridine (THA)
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine (THA) treatment during inpatient phase
Study: 1953964
Drug: Long-term outpatient
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term outpatient treatment with THA
Study: 31505491
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A (CsA) administered for 12 months after engraftment
Study: 26313245
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A (CsA)
Study: 27078993
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional drug therapy)
Study: 17936382
Drug: Impairment in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impairment in activities of daily living (ADL)
Study: 15126518
Drug: Buccal system
Normalized name: Striant 30mg Buccal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal system (Striant), applied twice daily for 7 days
Study: 15126518
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch (Andropatch or Androderm), applied daily for 7 days
Study: 7898078
Drug: Simvastatin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 2.5 mg
Study: 10563066
Drug: Cerivastatin 0.2
Normalized name: cerivastatin 0.2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.2 mg
Study: 7975414
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy with additional provision of vegetables, fruit, and greens
Study: 3547009
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of glucose in 350 ml of water (GLU)
Study: 3547009
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of fructose in 350 ml of water (FRU)
Study: 3547009
Drug: 350 ml
Normalized name: Nutrilipid 20 % in 350 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 ml of an artificially sweetened and flavored placebo (CON)
Study: 30580490
Drug: Activated carbon
Normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated carbon nanoparticles (ACNs) injection (1 ml) in the subserosa around the tumour before colectomy and D3 lymphadenectomy.
Study: 30580490
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ACN injection).
Study: 30580490
Drug: Activated carbon
Normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated carbon nanoparticles (ACNs) injection.
Study: 26427723
Drug: Trivalent-inactivated vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent-inactivated vaccine
Study: 26427723
Drug: Live-attenuated vaccine
Normalized name: Chikungunya vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated vaccine
Study: 23121733
Drug: CKD‐EPI eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD‐EPI eGFR <60 mL/min/1.73m2
Study: 23121733
Drug: Albuminuria with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuminuria with eGFR ≥60 mL/min/1.73 m2
Study: 23121733
Drug: MDRD related
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDRD related estimates for eGFR <60 mL/min/1.73 m2
Study: 19708471
Drug: Qigong Sensory
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Qigong Sensory Training (QST) - a qigong massage intervention, involving 20 sessions over 5 months, with daily parental massage.
Study: 18165528
Drug: Levamisole administered
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole administered bimonthly to 107 subjects
Study: 18165528
Drug: Levamisole administered
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole administered to children 5-14 years
Study: 3584580
Drug: PA Patch
Normalized name: Patch
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA Patch
Study: 31478095
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) + Exercise
Study: 28901958
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry juice (240 mL 2 times/d for 2 weeks)
Study: 24763930
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg once daily; 15 mg once daily for creatinine clearance of 30‐49 mL/min
Study: 20544937
Drug: Intramuscular BoNT‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular BoNT‐A injections at 6‐month intervals in the tibialis posterior and peroneus longus.
Study: 20544937
Drug: Control leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control leg received no injections.
Study: 17061020
Drug: Percussive ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percussive ventilation (IMP2 Breas, Sweden) 10 min twice/day in addition to chest physiotherapy
Study: 14581257
Drug: Dedicated medication
Normalized name: liver,desiccated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dedicated medication nurses
Study: 14581257
Drug: Dedicated medication
Normalized name: liver,desiccated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dedicated medication nurses at hospital B
Study: 14581257
Drug: Dedicated medication
Normalized name: liver,desiccated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dedicated medication nurses at hospital A
Study: 14581257
Drug: Dedicated medication
Normalized name: liver,desiccated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dedicated medication nurses in surgical units at hospital A
Study: 14581257
Drug: Dedicated medication
Normalized name: liver,desiccated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dedicated medication nurses in medical units
Study: 1573544
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid treatment for 30, 60, 120, or 240 seconds
Study: 1573544
Drug: Tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline HCl treatment for 30, 60, 120, or 240 seconds
Study: 3933330
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V given twice daily (250 mg for ten days)
Study: 3933330
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V given three times daily (250 mg for ten days)
Study: 24619932
Drug: LY2456302 (2-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2456302 (2-60 mg single doses)
Study: 24619932
Drug: LY2456302 (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2456302 (2, 10, and 35 mg multiple doses)
Study: 24619932
Drug: LY2456302 co-administered
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2456302 co-administered with ethanol
Study: 20076848
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily for five days
Study: 20076848
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg daily for five days
Study: 9502680
Drug: Pulse-spray thrombolysis
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-spray thrombolysis with high-dose urokinase
Study: 9502680
Drug: Continuous-infusion thrombolysis
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion thrombolysis with high-dose urokinase
Study: 7633701
Drug: Epinephrine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (2 mg bolus followed by 2 mg every 4 min)
Study: 7633701
Drug: Methoxamine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine (40 mg bolus followed after 4 min by 40 mg)
Study: 2520343
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, daily dose 4 x 0.1 mg for 6 weeks
Study: 20284
Drug: Clorazepate 15
Normalized name: clorazepate 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate 15 mg at bedtime
Study: 20284
Drug: Diazepam thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam thrice daily
Study: 26416334
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy with booster sessions
Study: 26416334
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus manual therapy
Study: 26416334
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus manual therapy with booster sessions
Study: 30545387
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (control group)
Study: 23583056
Drug: Topiramate monotherapy
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate monotherapy for ≥6 months
Study: 21713025
Drug: Ofloxacin treatment
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin treatment with MIC ≤0.125 µg/mL
Study: 21713025
Drug: Ofloxacin treatment
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin treatment with MIC between 0.25 and 0.50 µg/mL
Study: 21713025
Drug: Ofloxacin treatment
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin treatment with MIC 1.00 µg/mL
Study: 21713025
Drug: Ofloxacin treatment
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin treatment with MIC ≥0.25 µg/mL
Study: 15542798
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with four gp100‐ and tyrosinase‐derived peptides plus low-dose IL-2 administered daily beginning day 28 (group 2)
Study: 15542798
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with four gp100‐ and tyrosinase‐derived peptides plus low-dose IL-2 administered daily beginning day 7 (group 1)
Study: 3949375
Drug: Diltiazem monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem monotherapy for 8 weeks
Study: 3949375
Drug: Diltiazem therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem therapy in subjects with pretreatment glomerular filtration rates of 80 ml/min/1.73 m2 or less
Study: 31209428
Drug: Goserelin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin with chemotherapy
Study: 31209428
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without goserelin
Study: 26281052
Drug: FESS associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: FESS associated with inferior turbinate lateral fracture and radiofrequency ablation treatment
Study: 26281052
Drug: FESS associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: FESS associated with inferior turbinate lateral fracture treatment
Study: 12859126
Drug: High-quality center-based
Normalized name: COCONUT OIL 5 g in 30 mL TOPICAL OIL [High Quality Natural Rosemary]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quality center-based care for heavier LBW infants (2,001-2,500 g) for > 400 days
Study: 12859126
Drug: High-quality center-based
Normalized name: COCONUT OIL 5 g in 30 mL TOPICAL OIL [High Quality Natural Rosemary]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quality center-based care for lighter LBW infants (<= 2,000 g) for > 400 days
Study: 11063475
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention promoting a diet providing 28% of energy from total fat, <8% from saturated fat, </=9% from polyunsaturated fat, and <0.018 mg cholesterol*kJ(‐)(1)*d(‐)(1) (not to exceed 150 mg/d)
Study: 4036631
Drug: Nitrazepam 10
Normalized name: nitrazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 10 mg (NZ)
Study: 4036631
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg (TZ)
Study: 4036631
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg (DZ)
Study: 4036631
Drug: Alprazolam 0.25
Normalized name: alprazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.25 mg (AZ)
Study: 30141292
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at proximal and distal acupoints combined with NMES (20 min), oral function training (30 min), scalp acupuncture (1 h), body acupuncture (30 min), pricking blood at Jinjin and Yuye for patients of grade Ⅴ in TDS, treatment for 3 courses, 30 days, 5 times a week, once a day.
Study: 30141292
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at proximal and distal acupoints combined with NMES (20 min), oral function training (30 min).
Study: 30141292
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received NMES (20 min) and oral function training (30 min).
Study: 24326812
Drug: Ankaferd Blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankaferd Blood Stopper (ABS) - 1.0 mL administered to one half of the sockets
Study: 24326812
Drug: Physiological serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological serum - 1.0 mL irrigated in the control half of the sockets
Study: 12494164
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (diuretics and ACE inhibitors or ARBs)
Study: 9922681
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a topical and a systemic antibiotic
Study: 9922681
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial preparation
Study: 2081171
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of piperacillin 30 minutes before the operation
Study: 2081171
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of piperacillin 30 minutes before the operation
Study: 6781794
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of enantate testosterone and valerianate estradiol
Study: 29813149
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral vitamin D3 supplementation of 1200 IU